Search is Powered by Google
Pharma Industry / Biotech Industry News

House Committee Seeks Information On Marketing, 'Bundling' Contracts Related To Anemia Medications

Main Category: Pharma Industry / Biotech Industry
Also Included In: Public Health;  Cancer / Oncology;  Pharmacy / Pharmacist
Article Date: 02 Apr 2008 - 8:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

The House Energy and Commerce Committee has asked Amgen and Johnson & Johnson to submit information on marketing and "bundling" contracts related to anemia medications, which reports have linked with increased risk for death when administered at high doses, Bloomberg/Boston Globe reports.

The committee has requested information on the amount that J&J has spent on direct-to-consumer television and print advertisements for the anemia medication Procrit since 2001. In addition, the committee seeks an explanation of the decision by J&J to discontinue the ads for Procrit in 2005.

The committee has requested different information from Amgen, which does not market the anemia medications Epogen and Aranesp directly to consumers. The committee seeks copies of contracts under which Amgen provided discounts on Neupogen and Neulasta, medications that increase white blood cell production in cancer patients who receive chemotherapy, to physicians who prescribed Aranesp. The committee also has requested copies of TV and print ads for Neupogen and Neulasta.

In a March 31 letter to Amgen CEO Kevin Sharer, committee Chair John Dingell (D-Mich.) wrote, "We are concerned that such 'bundling' practices may have helped fuel excessive and dangerous off-label use of Aranesp."

Kassy McGourty -- a spokesperson for J&J subsidiary Ortho Biotech, which markets Procrit -- in an e-mail wrote, "We have received the letter from the House Committee on Energy and Commerce and will continue to cooperate fully with the committee's requests." Amgen did not immediately respond to an e-mail request for comment (Bloomberg/Boston Globe, 4/1).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Neulasta; Neupogen.





Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Schizophrenia

Sign up to receive newsletters / news alerts
MedReader RSS Reader


Hearing Babies Learn How to Communicate with Signs
Hearing Babies Learn How to Communicate with Signs

Learning sign language can help hearing children communicate before they can speak. Research indicates learning sign language may also boost IQ and help with reading skills. These families say it's fun, and it makes communicating with their little ones a lot easier.

more videos are available in our health videos section.